Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
Roy S. Herbst(The University of Texas MD Anderson Cancer Center), Rafat Ansari, F. Bustin(Centre hospitalier régional de la Citadelle), Patrick J. Flynn(Minnesota Oncology), Lowell L. Hart(Florida Cancer Specialists & Research Institute), Gregory A. Otterson(The Ohio State University Wexner Medical Center), Gordana Vlahovic(Duke Medical Center), Chang-Heok Soh, Paula G. O’Connor, John D. Hainsworth(Sarah Cannon)
Cited by 393Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis